Daniele Paone, Vice President, US Commercial Oncology, DNA Damage Response Franchise at AstraZeneca, shared on LinkedIn:
“The American Cancer Society has updated its prostate cancer screening guideline, and for the first time it makes a direct recommendation for regular PSA-based screening.
Prostate cancer is the second leading cause of cancer death in U.S. men.
This update aims to lower that toll by finding the disease earlier.
Updated recommendations:
- Average-risk men (ages 50-69): PSA-based screening every two years
- Higher-risk men (ages 45-69): Annual screening for Black men and men with a strong family history
- One first-degree relative diagnosed at 65 or older: Screening every two years from ages 45-69
- Ages 70-74: Individualized decision-making
- Elevated PSA: Repeat the test, then use MRI and/or a biomarker to guide biopsy decisions
- Low-risk disease: Active surveillance as the initial option
Why these changes?
Stronger evidence shows PSA screening reduces advanced-stage diagnoses and deaths, while better tools now help avoid unnecessary biopsies and treatment of slow-growing cancers.
Equity is central, too. Black men face a 67% higher incidence and nearly double the mortality of White men.
Earlier, more frequent screening is intended to help close that gap.
Knowing your risk and talking with your doctor is an important first step.”
You can also read:
Adam Weiner: ACS Makes Major Shift Toward Routine PSA-Based Prostate Cancer Screening.
American Cancer Society Journals Highlight New Evidence for PSA-Based Prostate Cancer Screening.
New Prostate Cancer Screening Guidelines Recommend Regular PSA Testing.
